Quarterly insights: Process technology
The war on coronavirus and innovation in process technology and services
We believe the worldwide effort to develop treatments and vaccines for COVID-19 will help transform global vaccine capabilities and be a catalyst to drive new, more productive technology platforms forward to commercialization.
The effort to approve and produce vaccines and treatments will provide an additional tailwind on top of already healthy growth in the pharma service and technology sector.
Given the urgent nature and large volume of any resulting vaccines, we assume they will face extreme price pressure and limited margins. Therefore, on a risk adjusted basis we think the companies best positioned to grow and profit as a result of these efforts are the providers of services and technology – the picks and shovels of the efforts – where productivity and technology tend to be rewarded.
TABLE OF CONTENTS
- Who are the players?
- Wars and races drive innovation and opportunity
- But it’s not just vaccines
- Select COVID-19 partnerships in the sector
- Interesting times ahead
- Process technology outperforms major indices, rallies to annual high
- Process technology M&A loses steam
- Process technology private investment slows during 1H20
Introduction
In our first Process Technology Quarterly Insights report, it is nearly impossible to not review the healthcare oriented players in the space and how they contribute to the war on COVID-19. The current effort to address the pandemic serves as an example of the power and flexibility of the evolving pharma technology and services sector, from fundamental research to packaging of drug product to meet healthcare needs. In addition, we believe innovation and adoption of new ways of operating prompted by these desperate times bodes well for the sector participants both in the short and long runs.
Request full report
To access the full report, please provide your contact information in the form below. Thank you for your interest in First Analysis research.